Читаем Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний полностью

Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний

Бастиан Блоэм , Майкл Окун , Рэй Дорси , Тодд Шерер

69. Olanow CW, Brundin P. Parkinson’s disease and alpha synuclein: is Parkinson’s disease a prion-like disorder? Movement Disorders. 2013;28(1):31–40; Uversky VN, Li J, Fink AL. Pesticides directly accelerate the rate of a-synuclein fibril formation: a possible factor in Parkinson’s disease. FEBS Letters. 2001;500(3):105–108.

70. Luk KC, Kehm V, Carroll J, et al. Pathological a-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949–953.

71. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nature Reviews Neurology. 2013;9(1):13–24.

72. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. a-synuclein in Lewy bodies. Nature. 1997;388:839–840; Mezey E, Dehejia AM, Harta G, et al. Alpha synuclein is present in Lewy bodies in sporadic Parkinson’s disease. Molecular Psychiatry. 1998;3:493–499.

73. Holdorff B. Friedrich Heinrich Lewy (1885–1950) and his work. Journal of the History of the Neurosciences. 2002;11(1):19–28.

74. Brin S. LRRK2. Too. September 18, 2008. http://too.blogspot. com/2008/09/lrrk2.html.

75. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601–607.

76. Там же.; Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson’s disease. The Lancet. 2005;365(9457):415–416; Di Fonzo A, Roh6 CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. The Lancet. 2005;365(9457):412–415.

77. Brin S. LRRK2. Too. September 18, 2008. http://too.blogspot. com/2008/09/lrrk2.html.

78. Там же.

79. Sergey Brin. Inside Philanthropy. www.insidephilanthropy.com/guide-to-individual-donors/sergey-brin.html. Accessed March 20, 2019; Goetz T. Sergey Brin’s search for a Parkinson’s cure. Wired. January 22, 2010. www.wired.com/2010/06/ff-sergeys-search. Accessed June 28, 2019.

80. The Associated Press. Twins study links Parkinson’s disease to the environment. New York Times. February 2, 1999.

81. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(1):a008888; Fleming SM. Mechanisms of gene-environment interactions in Parkinson’s disease. Current Environmental Health Reports. 2017;4(2):192–199.

82. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(1):a008888.

83. Fleming SM. Mechanisms of gene-environment interactions in Parkinson’s disease. Current Environmental Health Reports. 2017;4(2):192–199.

84. www.reuters.com/article/us-cancer-lung-nutrients-sb/nutrients-may-be-why-some-smokers-avoid-cancer-idUSTRE65E5JW20100616.

85. www.nature.com/articles/nature06846;www.nature.com/articles/ng.3892.

86. www.ncbi.nlm.nih.gov/pmc/articles/PMC4501942; https://pubmed. ncbi.nlm.nih.gov/ 28639421-penetrance-estimate-of-lrrk2-pg2019s-mutation-in-individuals-of-non-ashkenazi-jewish-ancestry.

87. Ryan SD, Dolatabadi N, Chan SF, et al. Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1a transcription. Cell. 2013;155(6):1351–1364.

88. Nuber S, Tadros D, Fields J, et al. Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactorystriatal interplay in early PD. Acta Neuropathologica. 2014;127(4):477–494.

89. Liu H-F, Ho PW-L, Leung GC-T, et al. Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease. Scientific Reports. 2017;7:40887. doi:10.1038/srep40887.

90. Weiner WJ. There is no Parkinson disease. Archives of Neurology. 2008;65(6):705–708.

91. Malek N, Weil RS, Bresner C, et al. Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study. Journal of Neurology, Neurosurgery & Psychiatry. 2018;89(7):702–709; Saunders-Pullman R, Mirelman A, Alcalay RN, et al. Progression in the LRRK2– associated Parkinson disease population. JAMA Neurology. 2018;75(3):312–319.

92. Parkinson J. An essay on the shaking palsy. Journal of Neuropsychiatry and Clinical Neurosciences. 2002;14(2):223–236.

Перейти на страницу: